<DOC>
	<DOCNO>NCT00715611</DOCNO>
	<brief_summary>For patient type cancer , standard care treatment chemotherapy . Radiation therapy typically use . This radiation entire lining lung many side effect often severe include damage lung ( pneumonitis ) . There new radiation technique use Intensity Modulated Radiation Therapy ( IMRT ) show reduce many side effect standard radiation therapy . This type radiation therapy specifically target line lung , cancer , reduces risk damage lung . The purpose study test safety implementation standard pleurectomy/decortication ( removal surface line lung ) perform center . Patients undergo pleurectomy/decortication chemotherapy hemithoracic pleural IMRT pleura patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Pleurectomy/Decortication ( Neo ) Adjuvant Chemotherapy Intensity Modulated Radiation Therapy Pleura Patients With Locally Advanced Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Provide write informed consent participate study Patients must pathologically confirm diagnosis either MSKCC participate site stage IIII malignant pleural mesothelioma Epithelioid biphasic histology subtype No evidence metastatic disease . Patient age ≥ 18 year ≤ 80 year time consent . Karnofsky performance status ≥ 80 % Pulmonary Function Tests : 1 . For patient : DLCO &gt; 40 % predict ( correct Hgb ) 2 . For patient enrol prior P/D , : FEV1 &gt; /= 35 % ( correct Hgb ) predict postoperative ( ppoFEV1 ) ( patient underwent pneumonectomy ) base follow formula use quantitative V/Q scan : Predicted postresection FEV1 = FEV1 x % perfusion uninvolved lung quantitative V/Q scan report In case concern decrease renal function potential high radiation dose kidney , optional nuclear medicine kidney function scan may perform prior radiation therapy determine functional contribution kidney . Patient enrol prior chemotherapy must adequate organ function indicate follow laboratory value : 1 . Absolute neutrophil count ≥1.5 K/mcL 2 . Platelets ≥100 K/mcL 3 . Serum total bilirubin ≤ 1.5 X ULN 4 . AST ( SGOT ) ALT ( SGPT ) ≤ 3.0 X ULN Note : patient enrol chemotherapy meet criterion Sarcomatoid desmoplastic histology Continuous oxygen use Prior nephrectomy contralateral side MPM Prior intrapleural therapy ( except pleurodesis ) intrapleural therapy time P/D ( i.e . : intrapleural chemotherapy , photodynamic therapy , intrapleural betadine ) Prior thoracic radiation therapy prevent hemithoracic pleural IMRT Bulky disease fissure prevent lungsparing pleural IMRT Patients undergoing extrapleural pneumonectomy Patients active infection require systemic antibiotic , antiviral , antifungal treatment Patients concurrent active malignancy ( except squamous basal cell carcinoma skin ) Patients serious unstable medical illness Presence third space fluid control drainage For patient develop baseline clinically significant pleural effusion initiation pemetrexed therapy ; consideration give drain effusion prior chemotherapy administration No acute congestive heart failure Pregnant lactate woman Men woman use effective contraception Reproductive risk Patients become pregnant father baby study drug study affect unborn baby . Women breastfeed baby study . Women childbearing age counsel use birth control study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pemetrexed</keyword>
	<keyword>cisplatin</keyword>
	<keyword>IMRT</keyword>
	<keyword>PLEURA</keyword>
	<keyword>Malignant</keyword>
	<keyword>08-053</keyword>
</DOC>